ClinicalTrials.gg
RecruitingNCT07819526CAT-AISUpdated Sep 21, 2026

Acute Ischemic Stroke in Patients With Active Cancer

An observational study in Acute Ischemic Stroke and Active Cancer, sponsored by Osaka University. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Osaka University · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Ischemic Stroke with a site in Japan — 7 open to participants now, 11 under way, 3 of them phase 3. Ischemic Stroke · Japan.

Started
2026
with 2 others
Observational
8 of 43
1 open now
Primary completion
2027-06
later than 4 of 10 live
Registered
43rd of 43
by date

Among the 43 studies in Ischemic Stroke with a site in Japan, this one is one of 3 that started in 2026, is one of 8 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 43rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Japan, or all of them as a file.
02

Study summary

The goal of this multicenter prospective observational study, conducted at 24 hospitals in Japan, is to learn about recurrent ischemic stroke in people with active cancer who develop acute ischemic stroke. One of the main objectives is to evaluate how often ischemic stroke recurs during follow-up.

The main questions this study aims to answer are:

  • How often does ischemic stroke recur within 3 months after the initial stroke?
  • Which clinical factors may be associated with recurrent ischemic stroke?
  • What other clinical outcomes occur during follow-up?

Participants will receive medical care determined by their treating physicians. Researchers will collect information about participants' cancer, stroke characteristics, test results, treatments, recurrent ischemic stroke, and other clinical outcomes. Researchers will also explore whether clinical factors are associated with recurrent ischemic stroke and other outcomes. This study will not assign participants to a specific treatment.

03

Conditions studied

  • Acute Ischemic Stroke
  • Active Cancer

Keywords

  • Cancer-associated ischemic stroke
  • Recurrent ischemic stroke
  • Cancer
  • Antithrombotic therapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of participants with acute ischemic stroke and active cancer who receive medical care at participating hospitals in Japan. Eligible participants will be enrolled prospectively during the study enrollment period.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute ischemic stroke diagnosed within 7 days after symptom onset or the time last known well.
  2. Active cancer at the time of the index stroke, as defined below.

Exclusion criteria

Exclusion Criteria:

  1. The patient or a legally acceptable representative indicates that the patient does not wish to participate.
  2. The investigator considers enrolment inappropriate.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Participants with acute ischemic stroke and active cancer

    Participants with active cancer who develop acute ischemic stroke and are enrolled prospectively at participating hospitals. Clinical information, treatments, recurrent ischemic stroke, and other outcomes will be collected during follow-up.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Recurrent Ischemic Stroke Within 3 Months

    The percentage of participants who experience recurrent ischemic stroke during follow-up. Recurrent ischemic stroke will be determined according to the criteria prespecified in the study protocol.

    Time frame: From enrollment through 3 months of follow-up

07

Study locations

1 of 1 sites recruiting
  • The Univeristy of Osaka
    Suita, Osaka 565-0871, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because no data-sharing plan has been established for this study. Study findings will be reported only in aggregate form.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 15 months is below that.

Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 15, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Mar 31, 2032
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07819526
Lead sponsor
Osaka University
Responsible party
Sponsor
First posted
Sep 15, 2026
Start date
Mar 1, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Mar 31, 2032 (estimated)
Last update
Sep 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion